Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mayne Pharma CEO Steps Down Amid $475m Metrics Contract Services Sale

CEO’s Departure Marks Turning Point For Mayne Pharma

Executive Summary

Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.

You may also be interested in...



Mayne Completes Divestment Of US Generics To Dr Reddy’s

Mayne Pharma and Dr Reddy’s have announced the completion of a deal that will see the Indian company take over the Australian firm’s US generics business.

Gloomy First Half Results For Mayne

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+

Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel